Cargando…
Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
SIMPLE SUMMARY: In this study we have isolated and analyzed atypical cells found in the blood of metastatic breast cancer patients using a micro-filtration technic. This technic, being very easy to implement, was also extremely useful for studying circulating tumors cells’ (CTCs) heterogeneity in ca...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869799/ https://www.ncbi.nlm.nih.gov/pubmed/35205679 http://dx.doi.org/10.3390/cancers14040932 |
_version_ | 1784656582834913280 |
---|---|
author | Lopresti, Alexia Acquaviva, Claire Boudin, Laurys Finetti, Pascal Garnier, Séverine Aulas, Anaïs Liberatoscioli, Maria Lucia Cabaud, Olivier Guille, Arnaud de Nonneville, Alexandre Da Costa, Quentin Denicolai, Emilie Pakradouni, Jihane Goncalves, Anthony Birnbaum, Daniel Bertucci, François Mamessier, Emilie |
author_facet | Lopresti, Alexia Acquaviva, Claire Boudin, Laurys Finetti, Pascal Garnier, Séverine Aulas, Anaïs Liberatoscioli, Maria Lucia Cabaud, Olivier Guille, Arnaud de Nonneville, Alexandre Da Costa, Quentin Denicolai, Emilie Pakradouni, Jihane Goncalves, Anthony Birnbaum, Daniel Bertucci, François Mamessier, Emilie |
author_sort | Lopresti, Alexia |
collection | PubMed |
description | SIMPLE SUMMARY: In this study we have isolated and analyzed atypical cells found in the blood of metastatic breast cancer patients using a micro-filtration technic. This technic, being very easy to implement, was also extremely useful for studying circulating tumors cells’ (CTCs) heterogeneity in cancer patients. We highlighted three subsets of CTCs, with different independent unfavorable prognostic values for progression-free and overall survival. We demonstrated that these cells can further be analyzed by immunofluorescence to narrow their molecular profiles and identify specific characteristics. Moreover, we identified a subset of CTCs, for which positivity might be a useful stratification tool to select patients more susceptible to benefit from early clinical trials testing novel therapeutics, which frequently enroll late-stage, already heavily pre-treated and thus poor-responder patients. ABSTRACT: Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer patients. Using a second-generation “filtration-based” technology to isolate CTCs, the Screencell™ technology (Sarcelles, France), we performed a large and simultaneous analysis of all atypical circulating tumor cells (aCTCs) isolated from the blood of metastatic breast cancer (mBC) patients. We correlated their presence with clinicopathological and survival data. We included 91 mBC patients from the PERMED-01 study. The median number of aCTCs was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter progression free survival and overall survival. This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels. In addition, it suggests the usefulness of the g-aCTC subset as a prognostic factor and a potential stratification tool to treat late-stage mBC patients and improve their chances of benefiting from early clinical trials. |
format | Online Article Text |
id | pubmed-8869799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88697992022-02-25 Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients Lopresti, Alexia Acquaviva, Claire Boudin, Laurys Finetti, Pascal Garnier, Séverine Aulas, Anaïs Liberatoscioli, Maria Lucia Cabaud, Olivier Guille, Arnaud de Nonneville, Alexandre Da Costa, Quentin Denicolai, Emilie Pakradouni, Jihane Goncalves, Anthony Birnbaum, Daniel Bertucci, François Mamessier, Emilie Cancers (Basel) Article SIMPLE SUMMARY: In this study we have isolated and analyzed atypical cells found in the blood of metastatic breast cancer patients using a micro-filtration technic. This technic, being very easy to implement, was also extremely useful for studying circulating tumors cells’ (CTCs) heterogeneity in cancer patients. We highlighted three subsets of CTCs, with different independent unfavorable prognostic values for progression-free and overall survival. We demonstrated that these cells can further be analyzed by immunofluorescence to narrow their molecular profiles and identify specific characteristics. Moreover, we identified a subset of CTCs, for which positivity might be a useful stratification tool to select patients more susceptible to benefit from early clinical trials testing novel therapeutics, which frequently enroll late-stage, already heavily pre-treated and thus poor-responder patients. ABSTRACT: Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer patients. Using a second-generation “filtration-based” technology to isolate CTCs, the Screencell™ technology (Sarcelles, France), we performed a large and simultaneous analysis of all atypical circulating tumor cells (aCTCs) isolated from the blood of metastatic breast cancer (mBC) patients. We correlated their presence with clinicopathological and survival data. We included 91 mBC patients from the PERMED-01 study. The median number of aCTCs was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter progression free survival and overall survival. This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels. In addition, it suggests the usefulness of the g-aCTC subset as a prognostic factor and a potential stratification tool to treat late-stage mBC patients and improve their chances of benefiting from early clinical trials. MDPI 2022-02-13 /pmc/articles/PMC8869799/ /pubmed/35205679 http://dx.doi.org/10.3390/cancers14040932 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lopresti, Alexia Acquaviva, Claire Boudin, Laurys Finetti, Pascal Garnier, Séverine Aulas, Anaïs Liberatoscioli, Maria Lucia Cabaud, Olivier Guille, Arnaud de Nonneville, Alexandre Da Costa, Quentin Denicolai, Emilie Pakradouni, Jihane Goncalves, Anthony Birnbaum, Daniel Bertucci, François Mamessier, Emilie Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title | Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title_full | Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title_fullStr | Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title_full_unstemmed | Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title_short | Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients |
title_sort | identification of atypical circulating tumor cells with prognostic value in metastatic breast cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869799/ https://www.ncbi.nlm.nih.gov/pubmed/35205679 http://dx.doi.org/10.3390/cancers14040932 |
work_keys_str_mv | AT loprestialexia identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT acquavivaclaire identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT boudinlaurys identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT finettipascal identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT garnierseverine identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT aulasanais identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT liberatosciolimarialucia identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT cabaudolivier identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT guillearnaud identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT denonnevillealexandre identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT dacostaquentin identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT denicolaiemilie identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT pakradounijihane identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT goncalvesanthony identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT birnbaumdaniel identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT bertuccifrancois identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients AT mamessieremilie identificationofatypicalcirculatingtumorcellswithprognosticvalueinmetastaticbreastcancerpatients |